Free tool
FAERS Monitor: Kimyrsa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214155 or its brand name (Kimyrsa, Oritavancin Diphosphate). Reports on generic versions are filed under their own applications.
Reports
297
Serious
98
33% of reports
Hospitalization
30
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- multiple use of single-use product109
- chills92
- infusion related reaction67
- off label use49
- back pain42
- dyspnoea38
- pruritus37
- tremor36
- flushing35
- nausea35
- rash25
- chest pain24
- vomiting23
- erythema17
- feeling cold17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 52 |
| 2023 | 144 |
| 2024 | 53 |
| 2025 | 35 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,862 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple use of single-use productSignal | 109 | 1402.1 | 1204.8 | 148,317 |
| infusion related reactionSignal | 67 | 71.7 | 58.0 | 4,607 |
| chillsSignal | 92 | 55.6 | 46.9 | 4,903 |
| feeling coldSignal | 17 | 43.3 | 27.3 | 661 |
| flushingSignal | 35 | 24.4 | 17.9 | 765 |
| tremorSignal | 36 | 15.4 | 11.3 | 473 |
| back painSignal | 42 | 12.8 | 9.7 | 450 |
| chest painSignal | 24 | 9.2 | 6.3 | 168 |
| pruritusSignal | 37 | 6.8 | 5.0 | 181 |
| erythemaSignal | 17 | 5.9 | 3.7 | 64 |
| dyspnoeaSignal | 38 | 4.8 | 3.5 | 112 |
| rashSignal | 25 | 4.1 | 2.8 | 56 |
| off label useSignal | 49 | 4.0 | 3.1 | 110 |
| vomitingSignal | 23 | 3.5 | 2.3 | 39 |
| nauseaSignal | 35 | 3.1 | 2.3 | 51 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.